Imam Jamil has smoldering myeloma, which is an inactive form of multiple myeloma. Individuals with smoldering myeloma generally are monitored without receiving treatment, although there are studies that indicate early intervention with medication could prevent the progression to active multiple myeloma.
The physicians at Butner FMC have not recommended that Imam Jamil receive any medication for his smoldering myeloma. They agree that he should be monitored and tested every two to three months to determine any progression of his condition. Imam Jamil has other medical conditions, which have not been addressed adequately at the Butner FMC.
1. Ask that Jamil Al-Amin is NOT returned to Florence ADX, and Request that he is NOT placed in solitary confinement because of his chronic medical state.
2. Request that Jamil Al-Amin is held - pending his appeals - at Butner, NC or a Georgia state facility to have access to his team of attorneys.
3. Request close monitoring and exploration of treatment for Jamil Al-Amin's medical conditions.
Charles E. Samuels, Jr., Director, Federal Bureau of Prisons, phone:202-307-3250
Dr. Newton E. Kendig, FBOP Medical Director
phone: 202-307-3055 e-mail: email@example.com
Eric Holder, Attorney General, DOJ 202-514-2001 DOJ public comment line, 202-353-1555, or AskDOJ@usdoj.gov
Office of General Counsel, Kathleen M. Kenny
The White House phone: 202-456-1414 www.bop.gov/inmates/concerns.jsp.
Select Butner FMC and #99974-555